Bank of New York Mellon
FENC icon

Bank of New York Mellon’s Fennec Pharmaceuticals FENC Stock Holding History

Bank of New York Mellon’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$656K Buy
61,032
+8,570
+16% +$70K ﹤0.01% 3608
2026
Q1 		$323K Buy
52,462
+3,243
+7% +$25K ﹤0.01% 3824
2025
Q4 		$379K Sell
49,219
-3,059
-6% -$25.1K ﹤0.01% 3743
2025
Q3 		$489K Buy
52,278
+466
+0.9% +$4.03K ﹤0.01% 3602
2025
Q2 		$430K Sell
51,812
-1,694
-3% -$11.6K ﹤0.01% 3592
2025
Q1 		$326K Buy
53,506
+1,378
+3% +$8.85K ﹤0.01% 3664
2024
Q4 		$329K Buy
52,128
+405
+0.8% +$2.07K ﹤0.01% 3732
2024
Q3 		$259K Sell
51,723
-17,001
-25% -$98.3K ﹤0.01% 3833
2024
Q2 		$420K Buy
68,724
+20,602
+43% +$171K ﹤0.01% 3672
2024
Q1 		$535K Buy
48,122
+2,129
+5% +$21.4K ﹤0.01% 3484
2023
Q4 		$516K Sell
45,993
-339
-0.7% -$2.81K ﹤0.01% 3534
2023
Q3 		$348K Buy
46,332
+1,090
+2% +$8.87K ﹤0.01% 3740
2023
Q2 		$399K Buy
+45,242
New +$376K ﹤0.01% 3709
2021
Q2 		– Sell
-44,912
Closed -$279K – 4420
2021
Q1 		$279K Sell
44,912
-954
-2% -$7.18K ﹤0.01% 3938
2020
Q4 		$342K Sell
45,866
-2,759
-6% -$21K ﹤0.01% 3777
2020
Q3 		$294K Buy
48,625
+186
+0.4% +$1.31K ﹤0.01% 3726
2020
Q2 		$404K Buy
+48,439
New +$360K ﹤0.01% 3579
2019
Q2 		– Sell
-22,804
Closed -$111K – 4235
2019
Q1 		$111K Hold
22,804
– – ﹤0.01% 3986
2018
Q4 		$145K Buy
22,804
+15
+0.1% +$105 ﹤0.01% 3909
2018
Q3 		$187K Hold
22,789
– – ﹤0.01% 3950
2018
Q2 		$237K Buy
+22,789
New +$270K ﹤0.01% 3887

Other funds holding FENC

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
HFM
Hartford Financial Management Hartford, Connecticut $448M AUM 32.11% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's FENC Position: Q2 2026 in Review

Bank of New York Mellon increased its Fennec Pharmaceuticals (FENC) stake by 16% in Q2 2026, buying an estimated $70K and bringing the position to 61,032 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #3608.

Bank of New York Mellon first reported a position in FENC in Q2 2018 and has held it in 21 quarters since. 37 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Bank of New York Mellon held 61,032 shares of Fennec Pharmaceuticals worth $656K as of Q2 2026.
  • Bank of New York Mellon bought 8,570 Fennec Pharmaceuticals shares in Q2 2026, an estimated $70K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3608 holding.
  • Bank of New York Mellon first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 21 quarters since.
  • 37 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.